If that email from JJ quoted by a certain Shareville username is genuine, then once again Faron’s management has blabbed information that pushes the boundaries of the Securities Markets Act.
Similar things can be found on other discussion forums as well. For instance, in the Kauppalehti (KL) Faron thread, a user named Saaristomeri wrote in a post on March 27, 2026, at 8:10 PM, that in hallway conversations after the extraordinary general meeting (EGM), JJ had mentioned knowing that in the FDA meeting, the clinicians supported accelerated approval (AA) for Bex, but the FDA’s financial department opposed it. So, the CEO is “gossiping” about internal divisions within the FDA’s processes, which surely aren’t normally public information.
Go figure 
These kinds of things could, of course, mostly stem from the writers’ own imaginations. But there’s no smoke without fire, as it’s known that Nasdaq’s disciplinary committee is investigating, among other things, the appropriateness of Faron’s disclosures. So, let’s wait for the committee’s decision.